Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Assets (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Non-Current Assets over the past 12 years, most recently at $5.2 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $5.2 million for Q4 2025, up 31.53% from a year ago — trailing twelve months through Dec 2025 was $17.7 million (up 10.47% YoY), and the annual figure for FY2025 was $5.2 million, up 31.53%.
  • Non-Current Assets for Q4 2025 was $5.2 million at Viridian Therapeutics, Inc.\DE, down from $5.2 million in the prior quarter.
  • Over the last five years, Non-Current Assets for VRDN hit a ceiling of $5.2 million in Q3 2025 and a floor of $1.3 million in Q1 2021.
  • Median Non-Current Assets over the past 5 years was $3.8 million (2022), compared with a mean of $3.9 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 279.21% in 2021 and later dropped 22.14% in 2024.
  • Viridian Therapeutics, Inc.\DE's Non-Current Assets stood at $3.5 million in 2021, then rose by 10.49% to $3.9 million in 2022, then increased by 0.71% to $3.9 million in 2023, then dropped by 0.1% to $3.9 million in 2024, then surged by 31.53% to $5.2 million in 2025.
  • The last three reported values for Non-Current Assets were $5.2 million (Q4 2025), $5.2 million (Q3 2025), and $3.6 million (Q2 2025) per Business Quant data.